Study identifier:NIS-OFR-IRE-2011/1
ClinicalTrials.gov identifier:NCT01448187
EudraCT identifier:N/A
CTIS identifier:N/A
Descriptive pharmacoepidemiological study of patients treated with Iressa
lung cancer
N/A
No
-
All
300
Observational
0 Years - 150 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jul 2016 by AstraZeneca
AstraZeneca
-
The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life
Descriptive pharmacoepidemiological study of patients treated with Iressa
Location
Location
AULNAY SOUS BOIS, France
Location
BAYONNE, France
Location
BORDEAUX, France
Location
BRON, France
Location
CARCASSONNE, France
Location
CHALON SUR SAONE, France
Location
CHOLET, France
Location
CLAMART, France
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.